Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
Author(s)
Tiong, IS; Loo, S;
Details
Publication Year 2023-03-01,Volume 24,Issue #5,Page 4790
Journal Title
International Journal of Molecular Sciences
Publication Type
Review
Abstract
Measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) has an established role in disease prognostication, particularly in guiding decisions for hematopoietic cell transplantation in first remission. Serial MRD assessment is now routinely recommended in the evaluation of treatment response and monitoring in AML by the European LeukemiaNet. The key question remains, however, if MRD in AML is clinically actionable or "does MRD merely portend fate"? With a series of new drug approvals since 2017, we now have more targeted and less toxic therapeutic options for the potential application of MRD-directed therapy. Recent approval of NPM1 MRD as a regulatory endpoint is also foreseen to drastically transform the clinical trial landscape such as biomarker-driven adaptive design. In this article, we will review (1) the emerging molecular MRD markers (such as non-DTA mutations, IDH1/2, and FLT3-ITD); (2) the impact of novel therapeutics on MRD endpoints; and (3) how MRD might be used as a predictive biomarker to guide therapy in AML beyond its prognostic role, which is the focus of two large collaborative trials: AMLM26 INTERCEPT (ACTRN12621000439842) and MyeloMATCH (NCT05564390).
Publisher
MDPI
Keywords
Humans; Hematopoietic Stem Cell Transplantation; *Leukemia, Myeloid, Acute/diagnosis/drug therapy; Neoplasm, Residual; Nuclear Proteins/genetics; Nucleophosmin/genetics; Remission Induction; Prognosis; Biomarkers, Tumor/genetics; Aml; Mrd; Npm1; novel therapy; relapse
Department(s)
Clinical Haematology; Pathology
PubMed ID
36902217
Open Access at Publisher's Site
https://doi.org/10.3390/ijms24054790
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-07-11 06:23:39
Last Modified: 2023-07-11 06:25:37

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙